Table 6. CMS classification of 458 CRCs.

RF_SSP	N	APC*	APC1 mut	APC2 mut	APC_ LOH	KRAS	TP53	TP53LOH	BRAF	MSI_H	Right	D_meta
CMS1†	77	32 ↓↓‡	18 ↓↓	14	1 ↓↓	22 ↓↓	44	13 ↓§	52 ↑↑	62 ↑↑	68 ↑↑	23
CMS2	116	90 ↑↑||	59 ↑↑	31	28 ↑↑	29 ↓	85 ↑↑	55 ↑↑	0 ↓↓	0 ↓↓	19 ↓↓	43
CMS3	64	72	36	36	22	73 ↑↑	39 ↓	23	5	8	48	14 ↓↓
CMS4	112	63	42	21	6	42	56	16 ↓	3 ↓↓	1 ↓↓	40	51 ↑↑
CMS_NA¶	89	70	45	25	8	51	61	20	7	6	44	29
Total#	458	307	192	115	61	190	275	125	52	59	188	160

APC, Adenomatous polyposis coli; CMS, consensus molecular subtype; CRC, colorectal cancer; MSI, microsatellite instability.

This table shows the distribution of four drivers, MSI status and distant metastasis (D_meta).

*APC represents all APC mutation statuses including APC 1 mut (one truncated mutation), APC 2 mut (two truncated mutations) and APC_LOH (inferred allelic loss).

Number in the table represents the per cent of interested observation in each CMS category, for example, 90% of CMS2 had APC mutations and 62% of CMS1 were MSI_H cases.

#Number in the ‘Total' row represents the number of cases.

There is significantly higher observation than expectation (||↑↑: P<0.01), based on individual χ² contribution from the table cell.

There is significantly lower observation than expectation ((§↓: P<0.05; ‡↓↓: P<0.01), based on individual χ² contribution from the table cell.

†The frequencies of MSI and BRAF mutation were higher in CMS1 but lower in CMS2, and, by contrast, APC mutations and TP53 ‘LOH' were seen in more CMS2 but were fewer in CMS1. Moreover, the CMS3 subtype was significantly associated positively with KRAS mutation, but negatively correlated with the rate of ‘developing' metastasis, while CMS4 tumours had fewer MSI but more ‘developing' metastasis cases.

¶CMS_NA, unclassified samples that were not applicable to CMS1-4.